J
Jo Varley-Campbell
Researcher at University of Exeter
Publications - 24
Citations - 600
Jo Varley-Campbell is an academic researcher from University of Exeter. The author has contributed to research in topics: Cost effectiveness & Panitumumab. The author has an hindex of 11, co-authored 23 publications receiving 369 citations. Previous affiliations of Jo Varley-Campbell include University College London.
Papers
More filters
Journal ArticleDOI
Defining the process to literature searching in systematic reviews: a literature review of guidance and supporting studies.
TL;DR: If a shared model of the literature searching process can be detected across systematic review guidance documents and, if so, how this process is reported in the guidance and supported by published studies is determined.
Journal ArticleDOI
Low-dose computed tomography for lung cancer screening in high-risk populations: a systematic review and economic evaluation.
Tristan Snowsill,Huiqin Yang,Ed Griffin,Linda Long,Jo Varley-Campbell,Helen Coelho,Sophie Robinson,Chris Hyde +7 more
TL;DR: LDCT screening may be clinically effective in reducing lung cancer mortality, but there is considerable uncertainty about the effect on costs and the magnitude of benefits, and screening programmes are predicted to be more effective than no screening, reduce lungcancer mortality and result in more lung cancer diagnoses.
Journal ArticleDOI
Immunosuppressive therapy for kidney transplantation in adults: a systematic review and economic model
Tracey Jones-Hughes,Tristan Snowsill,Marcela Haasova,Helen Coelho,Louise Crathorne,Chris Cooper,Ruben Mujica-Mota,Jaime Peters,Jo Varley-Campbell,Nicola Huxley,Jason Moore,Matt Allwood,Jenny Lowe,Chris Hyde,Martin Hoyle,Mary Bond,Rob Anderson +16 more
TL;DR: A new discrete time-state transition economic model (semi-Markov) was developed, with acute rejection, graft function (GRF) and new-onset diabetes mellitus used to extrapolate graft survival.
Journal ArticleDOI
The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review and economic evaluation.
Nicola Huxley,Louise Crathorne,Jo Varley-Campbell,Irina A Tikhonova,Tristan Snowsill,Simon Briscoe,Jaime Peters,Mary Bond,Mark Napier,Martin Hoyle +9 more
TL;DR: Although cetuximab and panitumumab in combination with chemotherapy appear to be clinically beneficial for RAS WT patients compared with chemotherapy alone, they are likely to represent poor value when judged by cost-effectiveness criteria currently used in the UK.
Journal ArticleDOI
Effect of Immobilisation on Neuromuscular Function In Vivo in Humans: A Systematic Review
Matthew I. Campbell,Jo Varley-Campbell,Jon Fulford,Bryan J. Taylor,Katya N. Mileva,Joanna L. Bowtell +5 more
TL;DR: Limb immobilisation results in non-uniform loss of isometric muscle strength, size and NMF over time, and different outcomes between upper and lower limbs could be attributed to higher degrees of central neural control of upper limb musculature.